Ambit Biosciences To Announce Second Quarter 2014 Financial Results

SAN DIEGO, July 29, 2014 /PRNewswire/ -- Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced it will report second quarter operational results after closing of the NASDAQ Global Market on Tuesday, August 12, 2014.

A conference call hosted by Michael Martino, president and CEO, and other members of senior management will take place on the same day at 5:00 pm EDT (2:00 pm PDT) and will be webcast live on the Ambit website. 

To access the live teleconference call, dial 866-436-9172 in the U.S. and 630-691-2760 for international callers.  Please specify to the operator that you would like to join the "Ambit Second Quarter 2014 Earnings Conference Call," referencing conference ID number 37609634. If you are unable to listen to the live webcast, a teleconference replay will be available through Tuesday, August 19, 2014.  Interested parties can access the replay by dialing 888-843-7419 and entering the passcode 37609634.

The conference call webcast is accessible through the "Investors & Media" section of the Ambit website at http://www.ambitbio.com.  An online replay will be available following the initial broadcast until Tuesday, September 9, 2014. 

About Ambit Biosciences
Ambit is a biopharmaceutical company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, autoimmune and inflammatory diseases by inhibiting kinases that are important drivers for those diseases. Ambit's lead drug candidate, quizartinib (AC220), is a once-daily, orally-administered potent and selective, inhibitor of FMS-like tyrosine kinase-3 (FLT3) and is currently in a registrational Phase 3 clinical trial, referred to as QUANTUM-R, in patients with relapsed/refractory FLT3-ITD positive, acute myeloid leukemia (AML).  Quizartinib is also being studied in newly diagnosed patients in combination with chemotherapy as well as maintenance following a hematopoietic stem cell transplantation (HSCT). In addition to quizartinib, Ambit's clinical pipeline includes AC410, an oral JAK2 inhibitor, and CEP-32496, a BRAF inhibitor licensed to Teva Pharmaceutical Industries Ltd. Ambit's preclinical portfolio includes a proprietary CSF1R inhibitor program.

SOURCE Ambit Biosciences